Moderna (MRNA) Q2 2026 Earnings Call Transcript
Moderna’s Q2 2026 earnings call covered pipeline updates and financial results. The company said it will add a Phase III cohort for norovirus vaccine mRNA-1403 after an interim analysis, and reported Q2 revenue of $145 million, net loss of $782 million, and cash and investments of $6.9 billion. Moderna reiterated 2026 revenue growth up to 10% and updated cost guidance.
How this was made
The 30-second read
Why it matters
The tradable elements are the updated 2026 cost-of-sales and R&D projections, the embedded litigation settlement charge, and the cash guidance range after the $950M payment.
Market read
Investors get a concrete earnings datapoint (Q2 revenue, loss, cash) plus a refreshed 2026 cost framework that includes litigation-related charges and manufacturing efficiency gains.
What to watch
Cash balance declines and the timing of the $950M settlement payment into Q3 could tighten near-term liquidity optics even as cost guidance improves.
Background
This is a Q2 2026 earnings call transcript covering pipeline updates, corporate/leadership announcements, and a revised 2026 financial framework.
Ticker impact
Moderna reports Q2 revenue of $145M, reiterates 2026 revenue growth up to 10%, and updates 2026 cost guidance after a $950M litigation settlement payment.
Likely modest volatility around guidance and cash burn expectations, with focus on whether manufacturing efficiency offsets ongoing R&D spend and settlement-related costs.
The transcript provides specific quarterly financials and revised 2026 cost-of-sales and R&D estimates, including the $0.9B litigation charge embedded in guidance. However, it does not include a new regulatory/product approval or a fresh clinical efficacy inflection that would typically drive a large repricing.
Market effects
Biopharma investors may recalibrate expectations for mRNA platform commercialization and cost discipline, especially around manufacturing efficiency and late-stage program wind-downs.
International revenue mix emphasis (UK, Canada, Australia partnerships) may influence sentiment toward non-US commercialization execution.
Ebola vaccine partnership expansion with CEPI reinforces ongoing global health demand narratives, but it is not quantified in financial terms here.
Counterpoint
The reiterated revenue growth target may mask underlying demand risk from COVID vaccination declines, and the transcript assumes no revenue from mFLUSIVA and mCOMBRIAX, limiting upside.
Key entities
- companyModerna
US-listed mRNA vaccine and therapeutics company providing Q2 results and updated 2026 revenue and cost guidance.
- organizationCEPI
Partnership expansion mentioned for exploring an Ebola vaccine development program.
- companyBiogen
Referenced as the prior employer of the newly appointed board member, Michael McDonnell.
